Cargando…
A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk
BACKGROUND: There is currently great interest in the incorporation of genetic susceptibility loci into screening models to identify individuals at high risk of disease. Here, we present the first risk prediction model including all 46 known genetic loci associated with rheumatoid arthritis (RA). MET...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283663/ https://www.ncbi.nlm.nih.gov/pubmed/24092415 http://dx.doi.org/10.1136/annrheumdis-2013-204133 |
_version_ | 1782351299289808896 |
---|---|
author | Yarwood, Annie Han, Buhm Raychaudhuri, Soumya Bowes, John Lunt, Mark Pappas, Dimitrios A Kremer, Joel Greenberg, Jeffrey D Plenge, Robert Worthington, Jane Barton, Anne Eyre, Steve |
author_facet | Yarwood, Annie Han, Buhm Raychaudhuri, Soumya Bowes, John Lunt, Mark Pappas, Dimitrios A Kremer, Joel Greenberg, Jeffrey D Plenge, Robert Worthington, Jane Barton, Anne Eyre, Steve |
author_sort | Yarwood, Annie |
collection | PubMed |
description | BACKGROUND: There is currently great interest in the incorporation of genetic susceptibility loci into screening models to identify individuals at high risk of disease. Here, we present the first risk prediction model including all 46 known genetic loci associated with rheumatoid arthritis (RA). METHODS: A weighted genetic risk score (wGRS) was created using 45 RA non-human leucocyte antigen (HLA) susceptibility loci, imputed amino acids at HLA-DRB1 (11, 71 and 74), HLA-DPB1 (position 9) HLA-B (position 9) and gender. The wGRS was tested in 11 366 RA cases and 15 489 healthy controls. The risk of developing RA was estimated using logistic regression by dividing the wGRS into quintiles. The ability of the wGRS to discriminate between cases and controls was assessed by receiver operator characteristic analysis and discrimination improvement tests. RESULTS: Individuals in the highest risk group showed significantly increased odds of developing anti-cyclic citrullinated peptide-positive RA compared to the lowest risk group (OR 27.13, 95% CI 23.70 to 31.05). The wGRS was validated in an independent cohort that showed similar results (area under the curve 0.78, OR 18.00, 95% CI 13.67 to 23.71). Comparison of the full wGRS with a wGRS in which HLA amino acids were replaced by a HLA tag single-nucleotide polymorphism showed a significant loss of sensitivity and specificity. CONCLUSIONS: Our study suggests that in RA, even when using all known genetic susceptibility variants, prediction performance remains modest; while this is insufficiently accurate for general population screening, it may prove of more use in targeted studies. Our study has also highlighted the importance of including HLA variation in risk prediction models. |
format | Online Article Text |
id | pubmed-4283663 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BMJ Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-42836632015-01-08 A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk Yarwood, Annie Han, Buhm Raychaudhuri, Soumya Bowes, John Lunt, Mark Pappas, Dimitrios A Kremer, Joel Greenberg, Jeffrey D Plenge, Robert Worthington, Jane Barton, Anne Eyre, Steve Ann Rheum Dis Clinical and Epidemiological Research BACKGROUND: There is currently great interest in the incorporation of genetic susceptibility loci into screening models to identify individuals at high risk of disease. Here, we present the first risk prediction model including all 46 known genetic loci associated with rheumatoid arthritis (RA). METHODS: A weighted genetic risk score (wGRS) was created using 45 RA non-human leucocyte antigen (HLA) susceptibility loci, imputed amino acids at HLA-DRB1 (11, 71 and 74), HLA-DPB1 (position 9) HLA-B (position 9) and gender. The wGRS was tested in 11 366 RA cases and 15 489 healthy controls. The risk of developing RA was estimated using logistic regression by dividing the wGRS into quintiles. The ability of the wGRS to discriminate between cases and controls was assessed by receiver operator characteristic analysis and discrimination improvement tests. RESULTS: Individuals in the highest risk group showed significantly increased odds of developing anti-cyclic citrullinated peptide-positive RA compared to the lowest risk group (OR 27.13, 95% CI 23.70 to 31.05). The wGRS was validated in an independent cohort that showed similar results (area under the curve 0.78, OR 18.00, 95% CI 13.67 to 23.71). Comparison of the full wGRS with a wGRS in which HLA amino acids were replaced by a HLA tag single-nucleotide polymorphism showed a significant loss of sensitivity and specificity. CONCLUSIONS: Our study suggests that in RA, even when using all known genetic susceptibility variants, prediction performance remains modest; while this is insufficiently accurate for general population screening, it may prove of more use in targeted studies. Our study has also highlighted the importance of including HLA variation in risk prediction models. BMJ Publishing Group 2015-01 2013-10-03 /pmc/articles/PMC4283663/ /pubmed/24092415 http://dx.doi.org/10.1136/annrheumdis-2013-204133 Text en Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ |
spellingShingle | Clinical and Epidemiological Research Yarwood, Annie Han, Buhm Raychaudhuri, Soumya Bowes, John Lunt, Mark Pappas, Dimitrios A Kremer, Joel Greenberg, Jeffrey D Plenge, Robert Worthington, Jane Barton, Anne Eyre, Steve A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title | A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title_full | A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title_fullStr | A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title_full_unstemmed | A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title_short | A weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
title_sort | weighted genetic risk score using all known susceptibility variants to estimate rheumatoid arthritis risk |
topic | Clinical and Epidemiological Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4283663/ https://www.ncbi.nlm.nih.gov/pubmed/24092415 http://dx.doi.org/10.1136/annrheumdis-2013-204133 |
work_keys_str_mv | AT yarwoodannie aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT hanbuhm aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT raychaudhurisoumya aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT bowesjohn aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT luntmark aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT pappasdimitriosa aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT kremerjoel aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT greenbergjeffreyd aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT plengerobert aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT worthingtonjane aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT bartonanne aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT eyresteve aweightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT yarwoodannie weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT hanbuhm weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT raychaudhurisoumya weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT bowesjohn weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT luntmark weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT pappasdimitriosa weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT kremerjoel weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT greenbergjeffreyd weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT plengerobert weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT worthingtonjane weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT bartonanne weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk AT eyresteve weightedgeneticriskscoreusingallknownsusceptibilityvariantstoestimaterheumatoidarthritisrisk |